Altered Linkage of Hydroxyacyl Chains in Lipid A of Campylobacter jejuni Reduces TLR4 Activation and Antimicrobial Resistance*

Received for publication, January 7, 2010, and in revised form, March 26, 2010. Published, JBC Papers in Press, March 29, 2010, DOI 10.1074/jbc.M110.102061

Andries van Mourik1, Liana Steeghs1, Jacoline van Laar1, Hugo D. Meiring2, Hendrik-Jan Hamstra1, Jos P. M. van Putten1, and Marc M. S. M. Wösten1,1

From the 1Department of Infectious Diseases and Immunology, Utrecht University, Yalelaan 1, 3584 CL Utrecht and The 1Netherlands Vaccine Institute (NVII), P. O. Box 457, 3720 AL Bilthoven, The Netherlands

The abbreviations used are: LPS, lipopolysaccharide; LOS, lipooligosaccharide; AMP, antimicrobial peptide; TLR, Toll-like receptor; Cm, chloramphenicol cassette; HI, heart infusion broth; Tricine, N-[2-hydroxy-1,1-bis[(hydroxymethyl)ethyl]glycine; h, human; ch, chicken; GlcN3N, 2,3-diamino-2,3-dideoxy-D-glucose; UDP-GlcNAc3N, UDP-2-acetamido-3-amino-2,3-dideoxy-α-D-glucopyranose.

Modification of the lipid A moiety of bacterial lipopolysaccharide influences cell wall properties, endotoxic activity, and bacterial resistance to antimicrobial peptides. Known modifications are variation in the number or length of acyl chains and/or attached phosphoryl groups. Here we identified two genes (gnnA and gnnB) in the major foodborne pathogen Campylobacter jejuni that enable the synthesis of a GlcN3N precursor UDP 2-acetamido-3-amino-2,3-dideoxy-α-D-glucopyranose (UDP-GlcNAc3N) in the lipid A backbone. Mass spectrometry of purified lipooligosaccharide verified that the gene products facilitate the formation of a 2,3-diamino-2,3-dideoxy-D-glucopyranose (GlcN3N) disaccharide lipid A backbone when compared with the β-1′-6-linked α-D-glucosamine (GlcN) disaccharide observed in Escherichia coli lipid A. Functional assays showed that inactivation of the gnnA or gnnB gene enhanced the TLR4-MD2-mediated NF-κB activation. The mutants also displayed increased susceptibility to killing by the antimicrobial peptides polymyxin B, colistin and the chicken cathelicidin-1. The gnnA and gnnB genes are organized in one operon with hemH, encoding a ferrochelatase catalyzing the last step in heme biosynthesis. These results indicate that lipid A modification resulting in amide-linked acyl chains in the lipid A is an effective mechanism to evade activation of the innate host defense and killing by antimicrobial peptides.

Lipopolysaccharide (LPS)2 is an amphipathic molecule that is an essential component of the outer membrane of most Gram-negative bacteria. LPS generally consists of three distinct structural domains: the lipid A moiety that anchors the molecule in the membrane, the core oligosaccharide, and a variable number of repeating oligosaccharide units, the O-antigen (1). LPS is not only critical for cell wall integrity, it is also one of the most potent activators of the innate immune system. LPS can activate the Toll-like receptor 4 (TLR4)-MD2 receptor complex, which triggers the production of proinflammatory mediators and antimicrobial peptides and indirectly steers the adaptive immune response (2–4).

To escape recognition by the innate immune system, Gram-negative bacteria have evolved several mechanisms to modify the structure of lipid A. Most lipid A-modifying enzymes are known to be regulated in response to changes in environmental conditions (5). The modifications can alter recognition by the TLR4 complex and/or promote resistance of the bacterial cell wall to host cationic antimicrobial peptides. The addition of polar groups, such as phosphoethanolamine, 4-amino-4-deoxy-1-arabinose, and/or palmitate, to the lipid A reduces its negative charge and limits its interaction with the cationic antibacterial polymyxin B or other antimicrobial peptides (AMPs) (6–9). Another mechanism of lipid A modification is to change the number of acyl chains attached to the disaccharide backbone. Hereto, Salmonella has the outer membrane enzymes PagP and PagL. The altered number of acyl chains increases the resistance to AMPs and decreases the cellular signaling through TLR4 (10, 11). This indicates that lipid A modifications can have immune-evasive as well as immune-modulating effects.

Biologically potent lipid A usually consists of a conserved β-1′-6-linked glucosamine (GlcN) disaccharide backbone with two ester- and two amide-linked acyl chains (12). Some bacterial species, including Leptospira interrogans and Acidithiobacillus ferrooxidans, can synthesize lipid A with only amide-linked acyl chains (GlcN3N). In A. ferrooxidans, the dehydrogenase (GnnA) and the transaminase (GnnB) convert UDP-GlcNAc to the analogue UDP-GlcNAc3N, in which the GlcNAc 3-ΟH group is replaced with an amine (13). Recombinant GnnA and GnnB from A. ferrooxidans, expressed in Escherichia coli, also yield large quantities of UDP-GlcNAc3N lipid A molecules. The possible immune-modulating or immune-evasive role of this type of modification of lipid A has thus far not been investigated (14).

Campylobacter jejuni is a Gram-negative spiral-shaped bacterium that causes gastrointestinal illness in humans. The LPS of C. jejuni lacks the O-antigen and therefore is often referred to as lipooligosaccharide (LOS). The structure of the Campylobacter LOS is highly variable, and this may contribute to modulation of the host innate immune response. Structural analysis of C. jejuni lipid A indicates that this bacterium displays heterogeneity in its lipid A (Fig. 1). The major structure of the C. jejuni lipid A contains a hybrid backbone of a β-1′-6-linked...
GlcN3N-GlcN disaccharide with two phosphate groups and six saturated fatty acids (15). C. jejuni has mixed lipid A with mainly three amide-linked acyl chains and only one ester-linked acyl chain instead of two ester- and two amide-linked acyl chains, present in most Enterobacteriaceae (16). It is proposed that lipid A with more hydroxyl-bound acyl chains is more biologically active toward TLR4 than lipid A with more amide-bound acyl chains (12, 16, 17). This might explain the reported difference in biological activity between E. coli and C. jejuni lipid A (12). In this study, we identified the C. jejuni genes responsible for adding amide-linked acyl chains in the lipid A and demonstrated that this modification influences the biological activity of lipid A by altering the TLR4 response and the bacterial resistance to antimicrobial peptides.

EXPERIMENTAL PROCEDURES

Bacterial Strains and Growth Conditions—The strains and plasmids used in this study are listed in Table 1. C. jejuni strains were routinely grown on plates containing blood agar base II (Oxoid, London, UK) supplemented with 5% horse blood (Biotrading Benelux b.v., Mijdrecht, The Netherlands) lysed with 0.5% saponin (Sigma) or in heart infusion broth (HI) (Oxoid) at 37 or 42 °C under microaerophilic conditions (5% O2, 10% CO2, 85% N2). E. coli strains were grown in Luria-Bertani medium (Biotrading) at 37 °C. When appropriate, medium was supplemented with chloramphenicol (20 μg/ml), kanamycin (50 μg/ml), and/or ampicillin (100 μg/ml).

Construction of C. jejuni gnnA:Cm and gnnB:Cm Mutants—The Campylobacter genes hemH, Cj0504c (gnnA), and Cj0505c (gnnB) were amplified by PCR using the primers HemHRev and 505Fwd (Table 2). The resulting fragment of 1912 bp was cloned into the pGEM-T easy vector (Promega Corp., Madison, WI) to form plasmid pGEMhemH-504-505. Inverse PCR using the primers Cj504BamHIR and Cj504BamHIF was performed on pGEMhemH-504-505 to replace 811 bp of the Cj0504 gene by a unique BamHI site. The inverse PCR product was self-ligated to form plasmid pGEMΔ504. The primers Cj505BamHIR and Cj505BamHIF were used in a similar procedure to replace 441 bp of the Cj0505 gene by a unique BamHI site. The pGEMΔ504 and pGEMΔ505 plasmids were digested with BamHI to insert a 0.7-kb BamHI chloramphenicol cassette (Cm) isolated from plasmid pAV35 (18). Both Cm orientations were selected, resulting in the plasmids pGEMΔ504:Cm, pGEMΔ504:CmR, pGEMΔ505:Cm, and pGEMΔ505::CmR. The plasmids isolated from E. coli DH5α were introduced into C. jejuni 11168H1 via electroporation. Homologous recombination resulting in double-crossover events was verified by PCR.

Complementation of C. jejuni gnnA::Cm and gnnB::Cm Mutants—To complement the C. jejuni gnnA:: Cm and gnnB::Cm mutants, a shuttle plasmid was constructed with intact copies of Cj0504c and Cj0505c.
Modification of Campylobacter jejuni lipid A

as insert. Therefore, the genes were amplified from the chromosome of C. jejuni strain 11168H1 by PCR with the primers Cj504stopXbal and Cj505startSacI and the proofreading enzyme platinum Pfx DNA polymerase (Invitrogen). After the addition of a 5’-A overhang to the PCR product with Taq polymerase (Invitrogen), the product was ligated into pGEM-T Easy to obtain plasmid pGEM504-505. Finally, pGEM504-505 and pMA1 (19) were digested with SacI and SallI, and the resulting 1986-bp fragment of pGEM504-505 was ligated into plasmid pMA1 behind the C. jejuni metK promoter to yield plasmid pMAI-504-505. E. coli S17 was used to conjugate plasmid pMAI-504-505 into C. jejuni gnnb::Cm, following described procedures (20).

Protoporphyrin IX Detection—For the detection of protoporphyrin IX, Campylobacter grown overnight in HI were harvested by centrifugation and resuspended in TEN buffer (40 mM Tris/HCl, pH 7.5, 1 mM EDTA, and 150 mM NaCl). Fluorescence of bacterial cells from 2 × 108 colony-forming units/ml was measured using an LS50B luminescence spectrometer (PerkinElmer Life Sciences) (excitation at 405 nm, emission at 630 nm) (21).

Isolation of LOS—C. jejuni LOS was isolated by the hot phenol extraction method as described (22). In brief, bacteria grown on blood agar plates for 20 h at 42 °C under microaerophilic conditions were harvested in 5 ml of water, pelleted by centrifugation (5500 × g, 30 min, 4 °C), and resuspended in 10 volumes of bacterial wet weight in distilled water and an equal volume of hot phenol (70 °C). After 2 h of incubation (70 °C) with intermittently vortexing and centrifugation (18,000 × g, 20 min, 4 °C), the water phase containing the LOS was collected. To increase the yield of LOS, a second extraction was done by adding an equal volume of distilled water to the phenol phase. LOS was precipitated from the water phase by adding an equal volume of distilled water to the phenol phase. The LOS sample was dissolved in 500 μl of distilled water and 500 μl of acetic acid (100 μl of 4 M HCl with 20 ml of 95% ethanol) followed by centrifugation (2000 × g, 10 min). To remove the acid, the sample was washed twice with non-acidified 95% ethanol and centrifuged (2000 × g, 10 min). The sample was lyophilized to yield solid lipid A. Just prior to the analysis, the sample was reconstituted in 200 μl of a mixture of chloroform/methanol/water (3:1.5:0.25, v/v), and a 10-μl aliquot of the clear supernatant was pipetted into a gold-coated borosilicate glass nanospray needle (manufactured in-house, essentially as described by Wilm and Mann (27)). A static nanoelectrospray source (built in-house) was mounted onto an LCQ Classic mass spectrometer (Thermo Scientific), operated in negative ion mode at mass unit resolution. The heated capillary was set at 200 °C, and the atmospheric pressure ionization source collision-induced dissociation energy (SIE) was enabled at 15 V. Automatic gain control was used to control the filling of the ion trap at a full mass spectrometry target of 1 × 105 ions. Scans were acquired from 400–2000 Da with 3 microscans and a maximum inject time of 150 ms.

Cell Culture, Transfection, and TLR Activation—The HeLa 57A cell line stably transfected with an NF-κB luciferase reporter construct (28) was routinely cultured in 25-cm2 tissue culture flasks (Corning) in Dulbecco’s modified Eagle’s medium (Invitrogen) with 5% fetal calf serum in a humidified incubator at 37 °C and 10% CO2. Transfection of the cells with plasmids encoding TLR4, MD2, and CD14 was essentially performed as described (29). After 48 h of incubation, the medium was replaced with fresh medium, and cells were stimulated (5 h) with the indicated concentrations of purified LOS. After stimulation with LOS, the cells were rinsed twice with 500 μl of Dulbecco’s phosphate-buffered saline (pH 7.4) and lysed in 100 μl of reporter lysis buffer (Promega) for 30 min at −80 °C. Firefly luciferase activity was measured with the luciferase assay system (Promega) using a luminometer (TD-20/20, Turner Designs, Sunnyvale, CA). The transfection efficiency was normalized using the β-galactosidase assay (Promega) as described (29).

Antimicrobial Peptide Susceptibility—Log phase bacteria grown at 42 °C in HI were resuspended to a concentration of 108 colony-forming units/ml in 10 mM sodium phosphate buffer, pH 7.0, supplemented with 1/100 volume HI medium (minimal HI medium) in 96-well polystyrene microtiter plates. After the addition of the indicated concentrations of polymyxin B, colistin E, or cathelicidin-1 and 1 h of incubation (37 °C, microaerophilic conditions), serial dilutions were plated.
Modification of Campylobacter jejuni lipid A

RESULTS

Identification of the Putative C. jejuni gnnA and gnnB Homologs—C. jejuni lipid A contains both GlcN saccharides and GlcN3N saccharides in contrast to E. coli LPS (12, 17). In A. ferrooxidans, the genes gnnA and gnnB are responsible for the synthesis of GlcN3N-containing lipid A (14). Bioinformatics revealed that the genome of C. jejuni strain 11168 contains two genes, Cj0504c and Cj0505c, which are respectively 40 and 55% similar at the amino acid level to the GnnA and GnnB proteins of A. ferrooxidans. The C. jejuni gnnA and gnnB gene and the downstream gene hemH, putatively involved in the protoheme biosynthesis, have a similar gene orientation and overlapping start and stop codons, suggesting that they may form an operon (Fig. 2A). The upstream gene alaS coding for an alanyl-tRNA synthetase has an opposite orientation, indicating that the promoter of the putative gnnB-gnnA-hemH operon may be located directly in front of gnnB. Genomic analysis of all C. jejuni genome sequences available in the public databases revealed a similar organization of the gnnB-gnnA-hemH genes in all strains.

Fluorescent Phenotype of C. jejuni gnnA and gnnB Mutants—To investigate the function of the putative gnnA and gnnB homologs in C. jejuni strain 11168, both genes were disrupted by insertion of a chloramphenicol resistance (Cm<sup>R</sup>) cassette in either orientation. PCR analysis verified that the desired four types of transformants (gnnA::Cm and gnnB::Cm with Cm<sup>R</sup> in two orientations) were obtained. Unexpectedly, the pellets of the mutants that contained the Cm<sup>R</sup> cassette in the opposite direction as the gnnA or gnnB genes appeared red. This red color was also visible when these mutants were grown on a transparent thioglycollate plate (Fig. 2B). Fluorescence microscopy revealed that these bacteria were intensely red fluorescent (data not shown). In other bacterial species, the HemH protein is involved in the protoheme biosynthesis and catalyzes the insertion of a ferrous ion into protoporphyrin IX to synthesize protoheme. Disruption of hemH in Pseudomonas fluorescens causes the accumulation of protoporphyrin, resulting in typical reddish colonies, which are highly fluorescent under UV light (21). To investigate whether the red fluorescence observed for the C. jejuni gnnA::Cm<sup>R</sup> and gnnB::Cm<sup>R</sup> mutants is due to the accumulation of protoporphyrin, we performed fluorescence spectrum analysis (Fig. 2C). This yielded a spectrum with a peak at 630 nm only for the mutants with the Cm<sup>R</sup> cassette in a polar orientation, which corresponds to that of protoporphyrin (21).

We hypothesized that the fluorescent bacterial phenotype may have been caused by a dampening effect of the Cm<sup>R</sup> promoter on the transcription of the hemH gene. Real-time reverse transcriptase-PCR analysis confirmed the strong reduction of hemH transcript in these gnnA and gnnB mutants. These results confirm that the genes gnnA, gnnB, and hemH are transcribed from a promotor in front of gnnB. To investigate whether the transcription of the gnnB-gnnA-hemH operon is altered in response to heme or oxidative stress, real-time reverse transcriptase-PCR analysis was performed on RNA isolated from bacteria grown in the presence of the heme precursor D-amino-levulinic acid, iron, dipyridyl, or H<sub>2</sub>O<sub>2</sub>. None of these conditions significantly changed the gnnB-gnnA-hemH transcript levels.

Further analysis of the transformants demonstrated that the gnnA and gnnB mutants that carried the Cm<sup>R</sup> cassette in the non-polar orientation were not fluorescent and showed parental growth rates and motility in semi-solid agar (data not shown). These mutants were used for further structural analysis of lipid A and in the biological assays described below.

LOS Structural Analysis—The main function of GnnA and GnnB in A. ferrooxidans is the biosynthesis of GlcN3N-substituted lipid A (13, 14). To analyze the linkage of the acyl chains in the lipid A of the C. jejuni gnnA::Cm or gnnB::Cm mutants, LOS was isolated from the mutants and parental strain after growth at the optimal C. jejuni growth temperature of 42 °C. Tricine-SDS-PAGE of these samples demonstrated similar electrophoretic mobility and staining of the LOS (Fig. 3A), indicating no large structural differences. To enable more detailed
Modification of Campylobacter jejuni lipid A
analysis of the lipid A, the different LOS samples were hydrolyzed and analyzed by static nanoelectrospray ionization mass spectrometry in the negative ion mode. This showed similar relative abundances of peaks for the lipid A of the wild-type and the mutant strains (Fig. 3B), indicating a similar distribution of lipid A isoforms. The lipid A of the wild type (Fig. 3B, upper trace) showed an abundant peak at a monoisotopic molecular ion of m/z 1877.9 Da, representing the hexa-acylated diphasate containing lipid A, whereas the peak at m/z 1798.0 Da corresponds to a hexa-acylated monophosphate species (30). Because of the heterogeneity of the constituents, we have confirmed these monoisotopic m/z values with higher mass resolution data acquisitions (data not shown). The remaining minor peaks at m/z 1770.2, 1849.9, and 2120.0 Da represent respectively hexa-acylated monophosphate species with a C14 instead of a C16 acyl chain, hexa-acylated diphasate species with a C14 instead of a C16 acyl chain, and hexa-acylated monophosphate species with a phosphoethanolamine. As expected, all peaks observed for the lipid A of the parent strain had shifted by two mass units in the gnnA::Cm and gnnB::Cm mutants, indicating substitution of one N-linked acyl chain by an O-linked acyl chain. To verify that this difference was solely due to disruption of the gnnK or gnnB gene, we analyzed the LOS of the gnnB mutant complemented in trans with plasmid pMA1-504-505. This plasmid contains intact copies of the gnnA and gnnB gene placed under the control of a constitutive (metK) promoter. Mass spectrometry demonstrated a decrease in lipid A masses to wild-type levels for the complemented gnnB mutant strain, although some heterogeneity in mass was observed (Fig. 3B, bottom panel). Overall, these results demonstrate that inactivation of either gnnA or gnnB results in replacement of one N-linked by an O-linked acyl chain in the lipid A.

Biological Activity of the gnnA::Cm and gnnB::Cm LOS—To investigate whether the type of linkage of the acyl chain is important for activation of the innate immune response by lipid A, we tested the effect of isolated gnnA and gnnB LOS on the activation of HeLa 57A cells transfected with plasmids containing TLR4, MD2, and CD14. Cellular activation was measured using the NF-κB luciferase reporter construct that is stably expressed by HeLa 57A cells (29). Incubation of the cells expressing the human TLR4-MD2 complex with the different purified LOS samples showed significant enhanced cellular activation for the mutant strains when compared with the parent strain at 1 ng/ml purified LOS and for the gnnB::Cm mutant also at 10 ng/ml (p < 0.05) (Fig. 4A). As TLR4 ligand specificity varies between species and chickens are a natural habitat for C. jejuni, we also evaluated the effect of the different LOS types on the activation of the chicken TLR4-MD2 complex. HeLa 57A cells transfected with chTLR4-chMD2 stimulated, with the different C. jejuni LOS, showed no difference in NF-κB activation (Fig. 4B), verifying that the effect of the lipid A modification varies between species. The increased activation of the human TLR4-MD2 complex by the mutant LOS was partially restored to wild-type levels after complementation of the gnnB mutant with pMA1-504-505. Overall, our results indicate that the substitution of an N-linked with an O-linked acyl chain in the lipid A results in a more biologically active LOS, at least in humans.

Modification of Lipid A with GlcN3N Influences Resistance to Antimicrobial Peptides—Modification of lipid A can alter the resistance to AMPs (31). To investigate whether the lipid A modification caused by C. jejuni GnnA and GnnB influenced the susceptibility to AMPs, we incubated log phase-grown wild-type strain 11168, the gnnA::Cm mutant, gnnB::Cm mutant, and the gnnB::Cm mutant complemented with pMA1-504-505. Values are indicated as -fold NF-κB increase and are the mean ± S.D. of four independent experiments. *, p < 0.05.

FIGURE 3. LOS structural analysis. A, silver-stained Tricine-SDS-PAGE gel loaded with equal amounts of LOS isolated from C. jejuni strain 11168 and its gnnA::Cm and gnnB::Cm derivatives grown at 42 °C. Wt, wild type; B, negative ion electrospray mass spectra of purified lipid A obtained from the wild-type strain, the gnnA::Cm mutant, the gnnB::Cm mutant, and the gnnB::Cm mutant strain containing the complementation plasmid pMA1-504-505 (top to bottom). Monoisotopic peaks at m/z 1798.0 and 1877.9 Da represent a hexa-acylated monophosphate species and the characteristic hexa-acylated diphasate, respectively. Three additional minor peaks were observed in all strains, the monoisotopic molecular ions corresponding to penta-acylated phosphoethanolamine (m/z 1770.2 Da), a hexa-acylated biphosphate species substituted with a C14 instead of a C16 acyl chain (m/z 1849.9 Da), and hexa-acylated lipid A with one phosphoethanolamine group attached to the lipid A (m/z 1921.0 Da).
Modification of Campylobacter jejuni lipid A

FIGURE 5. Susceptibility of gnnA::Cm and gnnB::Cm mutant bacteria to AMPs. Resistance to antimicrobial peptides of the C. jejuni strain 11168 wild type (Wt), the gnnA::Cm and gnnB::Cm mutants, and the gnnB::Cm mutant containing the complementation plasmid pMA1-504-505 is shown. Logarithmic phase bacteria were incubated for 1 h with 5 μg/ml polymyxin B (A), 5 μg/ml colistin E (B), and 0.1 μM chicken cathelicidin-1 (C). Bacterial survival was determined 24 h after plating of the suspensions on charcoal plates. Results are expressed as the percentage of the inoculum that survives the incubation, bacterial viability was determined by colony-forming unit counting. *p < 0.05.

DISCUSSION

Lipid A is the main constituent of the outer membrane of Gram-negative microorganisms and is the principal ligand of the innate immune receptor TLR4. During evolution, many bacteria have evolved enzymes that modify the lipid A structure and thus alter the physico-chemical and biological properties of the molecule. Here we identified two C. jejuni genes, gnnA and gnnB, that enable the addition of an N-linked acyl chain instead of an O-linked acyl chain to the disaccharide lipid A backbone. This modification decreases the potency of lipid A as a TLR4 agonist as demonstrated by the enhanced activation of the human TLR4-MD2 complex by purified LOS from the mutant microbes. In addition, these mutants are more susceptible to the antimicrobial peptides polymyxin B, colistin E, and chicken cathelicidin-1. The altered linkage of the acyl chain in the lipid A conferred by GnnA and GnnB may thus have evolved to enable the bacterium to resist the innate host defense.

The C. jejuni genes gnnA and gnnB are located in a single operon with hemH. This gene organization is conserved in all sequenced C. jejuni strains and Campylobacter lari but not in other Campylobacter strains or different bacterial species (13). The potential significance of the coordinated transcription of the gnnA/B and hemH genes is unknown. HemH is a protein that catalyzes the insertion of a ferrous ion into protoporphyrin IX to synthesize protoheme. In E. coli, hemH transcription is modestly increased in response to heme limitation (32). Furthermore, high heme concentrations cause lipid A modifications in the oral pathogen Porphyromonas gingivalis (33). The hemH gene in E. coli and Salmonella enterica is also activated in response to hydrogen peroxide (34, 35). We investigated whether the transcription of the gnnB-gnnA-hemH operon is altered in response to heme, the heme precursor d-aminolevulinic acid, iron, or H₂O₂, but none of these conditions significantly changed the gnnB-gnnA-hemH transcript levels.

The function of C. jejuni gnnA and gnnB in lipid A modification was established by mass spectrometry analyses of the isolated LOS of the wild-type and mutant strains. The observed two mass units increase of the lipid A isoforms for the mutants, which was reversed after introduction of an intact copy of the defective gene, indicates that inactivation of either gene caused the addition of an ester-linked acyl chain instead of an amide-linked acyl chain. This is fully consistent with the assumed function of GnnA and GnnB as lipid A-modifying enzymes as determined for A. ferrooxidans GnnA and GnnB (13, 14).

Our primary goal was to investigate the impact of variation in the number of amide-bound acyl chains on the biological properties of the lipid A. This was tested using the activation of NF-κB in HeLa cells transfected with genes encoding human or chicken TLR4-MD2 as a read-out system. This assay has previously been shown to be instrumental in demonstrating differences in TLR4 recognition of LOS species (29). Our finding that in this assay the purified LOS of the gnnA::Cm and gnnB::Cm mutants is more potent than wild-type LOS (Fig. 4A) provides for the first time an experimental basis for the hypothesis that lipid A containing GlcN3N-GlcN is less biologically active than lipid A that has a GlcN disaccharide backbone (16). The altered potency of the LOS was only detected toward the human TLR4-

mented gnnB mutant strain with increasing concentrations of polymyxin B, colistin E, or chicken cathelicidin-1. After 1 h of incubation, bacterial viability was determined by colony-forming unit counting. The gnnA and gnnB mutants showed at least 50% less survival to all three antimicrobial peptides when compared with the parental strain (Fig. 5). Equal survival percentages for the wild type and mutants were seen when antibiotics with a different bacterial target were used such as kanamycin (data not shown). The increased sensitivity of the gnnB mutant to AMPs was partially abolished in the complemented gnnB mutant strain. These data clearly demonstrate that the lipid A modification not only inhibits the activation of the innate immunity but also decreases the susceptibility to AMPs.
MD2 complex and not for cells expressing the chicken TLR4-MD2 receptor complex (Fig. 4B). These results are in agreement with previous work that indicates differences in ligand specificity of human, murine, and chicken TLR4 (36, 37). The altered potency of the LOS with variable acyl chain linkages extends the known repertoire of immune-modulating lipid A modifications such as variation in the length and number of acyl chains, the addition of polar groups, and variation in the number of phosphate molecules attached to the lipid A (5, 38).

The molecular basis for the variable potency of lipid A may be related to a decreased flexibility of the N-linked acyl chains when compared with the O-linked acyl chains (16). Crystal structures of the interaction between LPS and the TLR4-MD2 complex (PDB code 3FXI) have revealed that the number and the flexibility of the acyl chains might influence the interaction between lipid A and the TLR4-MD2 complex (39). We speculate that because the gnnA::Cm and gnnB::Cm mutants contain more flexible acyl chains in their LOS, the lipid A may fit more easily into the groove of the TLR4-MD2 complex, resulting in enhanced hTLR4 activation.

The composition of LPS may also have major effects on the bacterial resistance to antimicrobial agents. C. jejuni is very resistant to the AMP polymyxin B, a compound often added to medium to select for Campylobacter species (40). We observed that wild-type C. jejuni strain 11168 has a lower susceptibility to polymyxin B, colistin E, and cathelicidin-1 when compared with the gnnA::Cm and gnnB::Cm mutants. This suggests that the reduced number of N-linked acyl chains in the lipid A of the mutants causes increased sensitivity to AMPs. Bacterial killing by AMPs supposedly involves interaction of the small amphilic peptides with the negatively charged LPS. A number of Gram-negative pathogens resist AMPs by modifying their phosphoethanolamine (15), whereas phosphate molecules attached to the lipid A backbone appear important for cathelicidin-1 binding (42). Our mass spectrometry results indicate that apart from adding phosphate or phosphoethanolamine (15), C. jejuni exploits the gnnA and gnnB modification to increase its resistance to polymyxin B, colistin E, and cathelicidin-1 (Fig. 5). The altered resistance may be attributed to increased membrane stability and permeability caused by the amide linkage when compared with ester-linked acyl chains.

In conclusion, our results indicate a novel mechanism of lipid A modification in C. jejuni that involves GnnA- and GnnB-mediated replacement of an ester-linked by an amide-linked acyl chain in the lipid A. This results in a lipid A species with reduced endotoxin activity but increased bacterial resistance to antimicrobial peptides.

Acknowledgment—We thank Dr. A. van Dijk for providing AMP cathelicidin-1.

REFERENCES
1. Raetz, C. R., and Whitfield, C. (2002) Annu. Rev. Biochem. 71, 635–700
2. Pålsson-McDermott, E. M., and O’Neill, L. A. (2004) Immunology 113, 153–162
3. Kim, H. M., Park, B. S., Kim, J. I., Kim, S. E., Lee, J., Oh, S. C., Enkhabayar, P., Matsushima, N., Lee, H., Yoo, O. J., and Lee, J. O. (2007) Cell 130, 906–917
4. Miller, S. I., Ernst, R. K., and Bader, M. W. (2005) Nat. Rev. Microbiol. 3, 36–46
5. Raetz, C. R., Reynolds, C. M., Trent, M. S., and Bishop, R. E. (2007) Annu. Rev. Biochem. 76, 295–329
6. Guo, L., Lim, K. B., Poduje, C. M., Daniel, M., Gunn, J. S., Hackett, M., and Miller, S. I. (1998) Cell 95, 189–198
7. Trent, M. S., Ribeiro, A. A., Lin, S., Cotter, R. J., and Raetz, C. R. (2001) J. Biol. Chem. 276, 43122–43131
8. Lee, H., Hsu, F. F., Turk, J., and Groisman, E. A. (2004) J. Bacteriol. 186, 4124–4133
9. Zhou, Z., Ribeiro, A. A., Lin, S., Cotter, R. J., Miller, S. I., and Raetz, C. R. (2001) J. Biol. Chem. 276, 43111–43121
10. Bishop, R. E., Gibbons, H. S., Guina, T., Trent, M. S., Miller, S. I., and Raetz, C. R. (2000) EMBO J. 19, 5071–5080
11. Trent, M. S., Falsich, W., Raetz, C. R., and Miller, S. I. (2001) J. Biol. Chem. 276, 9083–9092
12. Schromm, A. B., Brandenburg, K., Lopponow, H., Moran, A. P., Koch, M. H., Rietschel, E. T., and Seydel, U. (2000) Eur. J. Biochem. 267, 2008–2013
13. Sweet, C. R., Ribeiro, A. A., and Raetz, C. R. (2004) J. Biol. Chem. 279, 25400–25410
14. Sweet, C. R., Williams, A. H., Karbarz, M. I., Werts, C., Kalb, S. R., Cotter, R. J., and Raetz, C. R. (2004) J. Biol. Chem. 279, 25411–25419
15. Moran, A. P., Zähringer, U., Seydel, U., Scholz, D. Stütz, P., and Rietschel, E. T. (1991) Eur. J. Biochem. 198, 459–469
16. Schromm, A. B., Brandenburg, K., Lopponow, H., Moran, A. P., Koch, M. H., Rietschel, E. T., and Seydel, U. (2000) Eur. J. Biochem. 267, 2008–2013
17. van Vliet, A. H., Wooldridge, K. G., and Ketley, J. M. (1998) J. Bacteriol. 180, 5291–5298
18. van Mourik, A., Bleumink-Pluym, N. M., van Dijk, L., van Putten, J. P., and Wösten, M. M. (2008) Microbiology 154, 584–592
19. Labigne-Roussel, A., Harel, J., and Tompkins, L. (1987) J. Bacteriol. 169, 5320–5323
20. Bayces, C., Matthijs, S., Pattery, T., and Cornelis, P. (2001) FEMS Microbiol. Lett. 205, 57–63
21. Keestra, A. M., and van Putten, J. P. (2008) J. Immunol. 181, 4354–4362
22. Lee, C. H., and Tsai, C. M. (1999) Anal. Biochem. 267, 161–168
23. Lee, C. H., and Tsai, C. M. (1999) Anal. Biochem. 267, 161–168
24. Lesse, A. J., Campagnari, A. A., Bittner, W. E., and Apicella, M. A. (1990) J. Immunol. Methods 126, 109–117
25. Tsai, C. M., and Frasch, C. E. (1982) J. Immunol. Methods 5, 57–63
26. Geurtsen, J., Angevaere, E., Janssen, M., Hamstra, H. J., ten Hove, J., de Haan, A., Kuipers, B., Tommassen, J., and van der Ley, P. (2007) J. Biol. Chem. 282, 25411–25419
27. Wilm, M. S., and Mann, M. (1994) Int. J. Mass Spectrom. Ion Processes 136, 167–180
28. Rodriguez, M. S., Thompson, J., Hay, R. T., and Dargemont, C. (1999) J. Biol. Chem. 274, 9081–9085
29. van Aubel, R. A., Keestra, A. M., Krooshoop, D. J., van Eden, W., and van Putten, J. P. (2007) Mol. Immunol. 44, 3702–3714
30. Marsden, G. L., Li, J., Everest, P. H., Lawson, A. J., and Ketley, J. M. (2009) J. Bacteriol. 191, 2392–2399
31. Peschel, A. (2002) Trends Microbiol. 10, 179–186
32. McNicholas, P. M., Javor, G., Darie, S., and Gunsalus, R. P. (1997) FEMS Microbiol. Lett. 146, 143–148
33. Coats, S. R., Jones, I. W., Do, C. T., Braham, P. H., Bainbridge, B. W., To, T. T., Goodlett, D. R., Ernst, R. K., and Darveau, R. P. (2009) Cell Microbiol. 11, 1587–1599
34. Zheng, M., Wang, X., Templeton, L. J., Smulski, D. R., LaRossa, R. A., and Storz, G. (2001) J. Bacteriol. 183, 4562–4570
35. Elfrardy-Weiss, M., Park, S., Schlosser-Silverman, E., Rosenthal, E., Imlay, J., and Altuvia, S. (2002) J. Bacteriol. 184, 3774–3784
Modification of Campylobacter jejuni lipid A

36. Steeghs, L., Keestra, A. M., van Mourik, A., Uronen-Hansson, H., van der Ley, P., Callard, R., Klein, N., and van Putten, J. P. (2008) Infect. Immun. 76, 3801–3807
37. Hajjar, A. M., Ernst, R. K., Tsai, J. H., Wilson, C. B., and Miller, S. I. (2002) Nat. Immunol. 3, 354–359
38. Raetz, C. R., Guan, Z., Ingram, B. O., Six, D. A., Song, F., Wang, X., and Zhao, J. (2009) J. Lipid Res. 50, S103–S108
39. Park, B. S., Song, D. H., Kim, H. M., Choi, B. S., Lee, H., and Lee, J. O. (2009) Nature 458, 1191–1195
40. Skirrow, M. B. (1977) Br. Med. J. 2, 9–11
41. Trent, M. S., Stead, C. M., Tran, A. X., and Hankins, J. V. (2006) J. Endotoxin Res. 12, 205–223
42. Bhunia, A., Mohanram, H., and Bhattacharjya, S. (2009) Biopolymers 92, 9–22
43. Szymanski, C. M., Michael, F. S., Jarrell, H. C., Li, J., Gilbert, M., Larocque, S., Vinogradov, E., and Brisson, J. R. (2003) J. Biol. Chem. 278, 24509–24520
44. Parkhill, J., Wren, B. W., Mungall, K., Ketley, J. M., Churcher, C., Basham, D., Chillingworth, T., Davies, R. M., Feltwell, T., Holroyd, S., Jagels, K., Karlyshev, A. V., Moule, S., Pallen, M. J., Penn, C. W., Quail, M. A., Rajendream, M. A., Rutherford, K. M., van Vliet, A. H., Whitehead, S., and Barrell, B. G. (2000) Nature 403, 665–668
45. Gundogdu, O., Bentley, S. D., Holden, M. T., Parkhill, J., Dorrell, N., and Wren, B. W. (2007) BMC Genomics 8, 162